<DOC>
	<DOCNO>NCT00877448</DOCNO>
	<brief_summary>A phase I/II , randomize , single-blind , placebo-controlled escalate double-dose safety study intramuscular universal influenza vaccine ( Multimeric-001 ) inject healthy volunteer .</brief_summary>
	<brief_title>A Double-Dose Safety Study An Influenza Vaccine ( Multimeric-001 )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male females 18 55 year ( inclusive ) age . Nonsmoking ( declaration ) period least 6 month . Subjects able adhere visit schedule protocol requirement available complete study . Haematology Chemistry value within normal range clinical significance Subjects provide write informed consent participate study Known history significant medical disorder , investigator 's judgment contraindicate administration study medication . Ongoing flu symptom influenza Any clinically significant abnormality upon physical examination clinical laboratory test screen visit . Treatment immune immunosuppressant drug immune enhance drug . Subjects immunized antiinfluenza vaccine infect influenza virus within one year prior screen visit . Administration vaccine 30 day screen visit . Known history drug alcohol abuse . Known history HIV , hepatitis C B virus ( HCV HBV ) Subjects know Guillain Barr√© Syndrome past 2 hospitalization within last year prior screen visit Increased liver enzymes 2.5 time upper reference level Known hypersensitivity and/or allergy drug Any acute medical situation ( e.g . acute infection ) within 48 hour study start , consider significance Principal Investigator . Subjects participate another clinical study within 30 day prior study entry Subjects noncooperative unwilling sign consent form . Pregnant lactate woman entry study unwilling agree continue precaution two month completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>INFLUENZA</keyword>
	<keyword>VACCINE</keyword>
	<keyword>UNIVERSAL</keyword>
	<keyword>SAFETY</keyword>
</DOC>